Robert Flavell, Md, Phd

This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …

This early study tests a radioactive imaging agent called 89Zr-Cimzia in 10 people with rheumatoid arthritis. The goal is to see if it can highlight inflamed joints on a PET scan, comparing painful joints to pain-free ones. The study is currently suspended, and it is exploratory,…

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…